Midodrine hydrochloride | CAS# 43218-56-0

MedKoo Cat#: 571128 | Name: Midodrine hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Midodrine hydrochloride is an ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. It improves clinical outcome of chronic hypotension.

Chemical Structure

Midodrine hydrochloride

CAS#43218-56-0 (HCl)

Theoretical Analysis

MedKoo Cat#: 571128

Name: Midodrine hydrochloride

CAS#: 43218-56-0 (HCl)

Chemical Formula: C12H19ClN2O4

Exact Mass: 290.1033

Molecular Weight: 290.74

Elemental Analysis: C, 49.57; H, 6.59; Cl, 12.19; N, 9.64; O, 22.01

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 300.00	2 weeks
250mg	USD 560.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

43218-56-0 (HCl) 42794-76-3 (free base) 133163-25-4 (R-isomer) 133267-39-7 (S-isomer)

Synonym

Midodrine hydrochloride; Amatine; Orvaten

IUPAC/Chemical Name

2-Amino-N-(2-(2,5-dimethoxyphenyl)-2-hydroxyethyl)acetamide monohydrochloride

InChi Key

MGCQZNBCJBRZDT-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H18N2O4.ClH/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13;/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16);1H

SMILES Code

O=C(NCC(C1=CC(OC)=CC=C1OC)O)CN.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Midodrine hydrochloride ((±)-Midodrine hydrochloride) is an α1-receptor agonist.

In vitro activity:

The chronotropic effects of midodrine, glycine (10(-8) to 3.10(-3) M), ST1059 and methoxamine (10(-8) to 10(-3) M) were investigated in the spontaneously beating guinea-pig right atrial preparation. Midodrine and glycine produced a slight, but significant rise in atrial rate over a wide concentration range. Reference: Agents Actions. 1976 Sep;6(5):584-8. https://pubmed.ncbi.nlm.nih.gov/61715/

In vivo activity:

The effect of CP-533,536 (0.03-0.3 mg/kg, intravenous [i.v.]) on urethral perfusion pressure (UPP) was investigated in anesthetized rats pre-treated with midodrine (1 mg/kg, i.v.), which forms an active metabolite that acts as an α1 -adrenoceptor agonist. CP-533,536 dose-dependently decreased UPP elevated by midodrine in anesthetized rats. In conscious rats, midodrine (1 mg/kg, i.v.) markedly increased RV and reduced VE. Reference: Low Urin Tract Symptoms. 2016 May;8(2):130-5. https://pubmed.ncbi.nlm.nih.gov/27111626/

	Solvent	mg/mL	mM
Solubility
	Water	100.0	343.95
	DMSO:PBS (pH 7.2) (1:1)	0.5	1.72

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 290.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Pittner H. Effects of midodrine, ST 1059, methoxamine and glycine on spontaneously beating guinea-pig atria. Agents Actions. 1976 Sep;6(5):584-8. doi: 10.1007/BF01971573. PMID: 61715. 2. Kurihara R, Imazumi K, Takamatsu H, Ishizu K, Yoshino T, Masuda N. Effect of Selective Prostaglandin E2 EP2 Receptor Agonist CP-533,536 on Voiding Efficiency in Rats with Midodrine-Induced Functional Urethral Obstruction. Low Urin Tract Symptoms. 2016 May;8(2):130-5. doi: 10.1111/luts.12080. Epub 2014 Nov 6. PMID: 27111626.

In vitro protocol:

1. Pittner H. Effects of midodrine, ST 1059, methoxamine and glycine on spontaneously beating guinea-pig atria. Agents Actions. 1976 Sep;6(5):584-8. doi: 10.1007/BF01971573. PMID: 61715.

In vivo protocol:

1. Kurihara R, Imazumi K, Takamatsu H, Ishizu K, Yoshino T, Masuda N. Effect of Selective Prostaglandin E2 EP2 Receptor Agonist CP-533,536 on Voiding Efficiency in Rats with Midodrine-Induced Functional Urethral Obstruction. Low Urin Tract Symptoms. 2016 May;8(2):130-5. doi: 10.1111/luts.12080. Epub 2014 Nov 6. PMID: 27111626.

1: Zhao J, Tang C, Jin H, Du J. Plasma copeptin and therapeutic effectiveness of midodrine hydrochloride on postural tachycardia syndrome in children. J Pediatr. 2014 Aug;165(2):290-294.e1. doi: 10.1016/j.jpeds.2014.04.032. Epub 2014 May 22. PubMed PMID: 24857518. 2: Jans Ø, Mehlsen J, Kjærsgaard-Andersen P, Husted H, Solgaard S, Josiassen J, Lunn TH, Kehlet H. Oral Midodrine Hydrochloride for Prevention of Orthostatic Hypotension during Early Mobilization after Hip Arthroplasty: A Randomized, Double-blind, Placebo-controlled Trial. Anesthesiology. 2015 Dec;123(6):1292-300. doi: 10.1097/ALN.0000000000000890. PubMed PMID: 26492477. 3: Yang J, Zhao J, Du S, Liu D, Fu C, Li X, Chen S, Tang C, Du J, Jin H. Postural orthostatic tachycardia syndrome with increased erythrocytic hydrogen sulfide and response to midodrine hydrochloride. J Pediatr. 2013 Oct;163(4):1169-73.e2. doi: 10.1016/j.jpeds.2013.04.039. Epub 2013 May 30. PubMed PMID: 23726544. 4: Izcovich A, González Malla C, Manzotti M, Catalano HN, Guyatt G. Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review. Neurology. 2014 Sep 23;83(13):1170-7. doi: 10.1212/WNL.0000000000000815. Epub 2014 Aug 22. Review. PubMed PMID: 25150287. 5: Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, Raj SR, Robertson D, Biaggioni I, Shibao CA. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014 Dec;64(6):1235-40. doi: 10.1161/HYPERTENSIONAHA.114.04225. Epub 2014 Sep 2. PubMed PMID: 25185131; PubMed Central PMCID: PMC4231172. 6: Deng W, Liu Y, Liu AD, Holmberg L, Ochs T, Li X, Yang J, Tang C, Du J, Jin H. Difference between supine and upright blood pressure associates to the efficacy of midodrine on postural orthostatic tachycardia syndrome (POTS) in children. Pediatr Cardiol. 2014 Apr;35(4):719-25. doi: 10.1007/s00246-013-0843-9. Epub 2013 Nov 20. PubMed PMID: 24253613. 7: Li H, Zhang F, Wang Y, Liu P, Zhang C, Feng X, Du J, Jin H. [Predictive value of baseline plasma midregional fragment of pro-adrenomedullin level on long-term outcome of postural tachycardia syndrome children treated with midodrine hydrochloride]. Zhonghua Xin Xue Guan Bing Za Zhi. 2015 Jun;43(6):507-10. Chinese. PubMed PMID: 26420118. 8: Levine AR, Meyer MJ, Bittner EA, Berg S, Kalman R, Stanislaus AB, Ryan C, Ball SA, Eikermann M. Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions. J Crit Care. 2013 Oct;28(5):756-62. doi: 10.1016/j.jcrc.2013.05.021. Epub 2013 Jul 8. PubMed PMID: 23845791. 9: Whitson MR, Mo E, Nabi T, Healy L, Koenig S, Narasimhan M, Mayo PH. Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock. Chest. 2016 Jun;149(6):1380-3. doi: 10.1016/j.chest.2016.02.657. Epub 2016 Mar 4. PubMed PMID: 26953217. 10: Zhang F, Li X, Ochs T, Chen L, Liao Y, Tang C, Jin H, Du J. Midregional pro-adrenomedullin as a predictor for therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2012 Jul 24;60(4):315-20. doi: 10.1016/j.jacc.2012.04.025. PubMed PMID: 22813609. 11: Poveromo LB, Michalets EL, Sutherland SE. Midodrine for the weaning of vasopressor infusions. J Clin Pharm Ther. 2016 Jun;41(3):260-5. doi: 10.1111/jcpt.12375. Epub 2016 Mar 4. PubMed PMID: 26945564. 12: Ali A, Farid S, Amin M, Kassem M, Al-Garem N. Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial. Hepatogastroenterology. 2014 Oct;61(135):1915-24. PubMed PMID: 25713888. 13: Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015 Aug;62(2):567-74. doi: 10.1002/hep.27709. Epub 2015 Feb 13. PubMed PMID: 25644760. 14: Liao Y, Yang J, Zhang F, Chen S, Liu X, Zhang Q, Ai Y, Wang Y, Tang C, Du J, Jin H. Flow-mediated vasodilation as a predictor of therapeutic response to midodrine hydrochloride in children with postural orthostatic tachycardia syndrome. Am J Cardiol. 2013 Sep 15;112(6):816-20. doi: 10.1016/j.amjcard.2013.05.008. Epub 2013 Jun 1. PubMed PMID: 23735645. 15: Smith W, Wan H, Much D, Robinson AG, Martin P. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clin Auton Res. 2016 Aug;26(4):269-77. doi: 10.1007/s10286-016-0363-9. Epub 2016 Jul 2. PubMed PMID: 27372462; PubMed Central PMCID: PMC4951503. 16: Chen L, Wang L, Sun J, Qin J, Tang C, Jin H, Du J. Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome. Circ J. 2011;75(4):927-31. Epub 2011 Feb 2. PubMed PMID: 21301135. 17: Phillips AA, Warburton DE, Ainslie PN, Krassioukov AV. Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride. J Cereb Blood Flow Metab. 2014 May;34(5):794-801. doi: 10.1038/jcbfm.2014.3. Epub 2014 Jan 29. PubMed PMID: 24473484; PubMed Central PMCID: PMC4013775. 18: Parsaik AK, Singh B, Altayar O, Mascarenhas SS, Singh SK, Erwin PJ, Murad MH. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med. 2013 Nov;28(11):1496-503. doi: 10.1007/s11606-013-2520-3. Epub 2013 Jun 18. Review. PubMed PMID: 23775146; PubMed Central PMCID: PMC3797331. 19: Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta PK. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. J Hepatol. 2012 Feb;56(2):348-54. doi: 10.1016/j.jhep.2011.04.027. Epub 2011 Jul 13. PubMed PMID: 21749847. 20: Chen J, Du J. [Progress in the treatment of postural tachycardia syndrome with midodrine hydrochloride in children]. Zhonghua Er Ke Za Zhi. 2015 May;53(5):397-9. Chinese. PubMed PMID: 26080677.